People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...

DUBLIN - GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company valued at $551.5 million, announced today significant results from its Phase 2b clinical trial for GH001, an ...

Dr. Villy Valcheva, CEO of GH Research, expressed optimism about the trial's results, stating, "Today, as we share our unprecedented positive Phase 2b data, we celebrate a significant milestone in our ...

A new clinic in Stratford is offering ketamine treatment to help people with mental health conditions.Ketamine has been used ...

PLC reported the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase 2b clinical trial with ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...